Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

v3.24.2.u1
Operating Segments (Tables)
6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information

Segment Reporting for the Quarter Ended June 30, 2024

 

                (1)    
    Treatment   Services   Segments Total   Corporate (1)   Consolidated Total
Revenue from external customers   $ 8,343     $ 5,643     $ 13,986     $ —   $ 13,986  
Intercompany revenues     9       13       22       —     —    
Gross loss     (1,197 )     (109 )     (1,306 )     —     (1,306 )
Research and development     186       24       210       63       273  
Interest income     —     —     —     213       213  
Interest expense     (33 )     (2 )     (35 )     (74 )     (109 )
Interest expense-financing fees     —     —     —       (16 )     (16 )
Depreciation and amortization     367       44       411       19       430  
Segment loss     (1,668 )     (462 )     (2,130 )     (1,655 )     (3,785 )
Expenditures for segment assets     457       140       597       —       597 (2)

 

Segment Reporting for the Six Months Ended June 30, 2024

 

                (1)    
    Treatment   Services   Segments Total   Corporate (1)   Consolidated Total
Revenue from external customers   $ 17,052     $ 10,551     $ 27,603     $ —     $ 27,603   
Intercompany revenues     54       29       83       —       —   
Gross loss     (1,249 )     (677 )     (1,926 )     —       (1,926 )
Research and development     404       52       456       113       569   
Interest income     —       —       —       387       387   
Interest expense     (69 )     (2 )     (71 )     (154 )     (225 )
Interest expense-financing fees     —       —       —       (29 )     (29 )
Depreciation and amortization     733       89       822       40       862
Segment loss     (2,514 )     (1,419 )     (3,933 )     (3,310 )     (7,243 )
Expenditures for segment assets     617       224       841       —       841 (2)

 

Segment Reporting for the Quarter Ended June 30, 2023

 

                (1)    
    Treatment   Services   Segments Total   Corporate (1)   Consolidated Total
Revenue from external customers   $ 12,834     $ 12,198     $ 25,032     $ —     $ 25,032  
Intercompany revenues     26       17       43       —       —  
Gross profit     2,491       2,025       4,516       —       4,516  
Research and development     91       7       98       23       121  
Interest income     —       —       —       172       172  
Interest expense     (23 )     —       (23 )     (24 )     (47 )
Interest expense-financing fees     —       —       —       (24 )     (24 )
Depreciation and amortization     589       89       678       14       692  
Segment income (loss)     1,273       840       2,113       (1,594 )     519  
Expenditures for segment assets     293       5       298       —       298 (3)

 

Segment Reporting for the Six Months Ended June 30, 2023

 

                (1)    
    Treatment   Services   Segments Total   Corporate (1)   Consolidated Total
Revenue from external customers   $ 22,428     $ 22,711     $ 45,139     $ —     $ 45,139  
Intercompany revenues     230       36       266       —       —  
Gross profit     3,743       3,782       7,525       —       7,525  
Research and development     158       10       168       52       220  
Interest income     —       —       —       298       298  
Interest expense     (45 )     (1 )     (46 )     (54 )     (100 )
Interest expense-financing fees     —       —       —       (44 )     (44 )
Depreciation and amortization     1,162       249       1,411       28       1,439  
Segment income (loss)     1,605       1,813       3,418       (3,216 )     202  
Expenditures for segment assets     1,043       4       1,047       —       1,047 (3)

 

  (1) Amounts reflect the activity for corporate headquarters not included in the segment information.
     
  (2) Net of financed amount of $0 and $44,000 for the three and six months ended June 30, 2024, respectively.
     
  (3) Net of financed amount of $107,000 and $157,000 for the three and six months ended June 30, 2023, respectively.